Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern

Detalhes bibliográficos
Autor(a) principal: Azevedo, Patrick Orestes
Data de Publicação: 2023
Outros Autores: Souza, Natália Satchiko Hojo de, Faustino, Lídia Paula, Fumagalli, Marcílio Jorge, Hirako, Isabella Cristina, Oliveira, Emiliano R., Figueiredo, Maria M., Carvalho, Alex F., Doro, Daniel, Benevides, Luciana, Durigon, Edison, Fonseca, Flávio Guimaraes, Machado, Alexandre Magalhaes, Fernandes, Ana P., Teixeira, Santuza Maria Ribeiro, Silva, João S., Gazzinelli, Ricardo Tostes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/57372
Resumo: Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
id CRUZ_fe7386d717508e949dc54ec2e425fc30
oai_identifier_str oai:www.arca.fiocruz.br:icict/57372
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Azevedo, Patrick OrestesSouza, Natália Satchiko Hojo deFaustino, Lídia PaulaFumagalli, Marcílio JorgeHirako, Isabella CristinaOliveira, Emiliano R.Figueiredo, Maria M.Carvalho, Alex F.Doro, DanielBenevides, LucianaDurigon, EdisonFonseca, Flávio GuimaraesMachado, Alexandre MagalhaesFernandes, Ana P.Teixeira, Santuza Maria RibeiroSilva, João S.Gazzinelli, Ricardo Tostes2023-03-14T18:45:40Z2023-03-14T18:45:40Z2023AZEVEDO, Patrick Orestes et al. Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. NPJ Vaccines, v. 8, p. 1-17, 2023.2059-0105https://www.arca.fiocruz.br/handle/icict/5737210.1038/s41541-023-00616-yengNatureDifferential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concerninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.Universidade de São Paulo. Faculdade de Medicina de Ribeirão Preto. São Paulo, SP, Brazil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.Fundação Oswaldo Cruz. Plataforma Bi-Institucional de Pesquisa em Medicina Translacional. São Paulo, SP, Brazil.Universidade de São Paulo. Instituto de Ciências Biológicas. São Paulo, SP, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Universidade Federal de Minas Gerais. Faculdade de Farmácia. Belo Horizonte, MG, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Belo Horizonte, MG, Brazil.Fundação Oswaldo Cruz. Plataforma Bi-Institucional de Pesquisa em Medicina Translacional. São Paulo, SP, Brazil.Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil / Universidade de São Paulo. Faculdade de Medicina de Ribeirão Preto. São Paulo, SP, Brazil / Fundação Oswaldo Cruz. Plataforma Bi-Institucional de Pesquisa em Medicina Translacional. São Paulo, SP, Brazil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Belo Horizonte, MG, Brazil / University of Massachusetts Medical School. Worcester, MA, USA.The current COVID-19 vaccines protect against severe disease, but are not effective in controlling replication of the Variants of Concern (VOCs). Here, we used the existing pre-clinical models of severe and moderate COVID-19 to evaluate the efficacy of a Spike-based DNA vaccine (pCTV-WS) for protection against different VOCs. Immunization of transgenic (K18-hACE2) mice and hamsters induced significant levels of neutralizing antibodies (nAbs) to Wuhan and Delta isolates, but not to the Gamma and Omicron variants. Nevertheless, the pCTV-WS vaccine offered significant protection to all VOCs. Consistently, protection against lung pathology and viral load to Wuhan or Delta was mediated by nAbs, whereas in the absence of nAbs, T cells controlled viral replication, disease and lethality in mice infected with either the Gamma or Omicron variants. Hence, considering the conserved nature of CD4 and CD8 T cell epitopes, we corroborate the hypothesis that induction of effector T-cells should be a main goal for new vaccines against the emergent SARS-CoV-2 VOCs.SARS-CoV-2COVID-19Variants of Concern (VOCs)info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/57372/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALDifferential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern.pdfDifferential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern.pdfapplication/pdf7019134https://www.arca.fiocruz.br/bitstream/icict/57372/2/Differential%20requirement%20of%20neutralizing%20antibodies%20and%20T%20cells%20on%20protective%20immunity%20to%20SARS-CoV-2%20variants%20of%20concern.pdf081754fe85f7ba91d31f7803c1fa0fa0MD52icict/573722023-11-08 13:44:36.586oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-11-08T16:44:36Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
title Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
spellingShingle Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
Azevedo, Patrick Orestes
SARS-CoV-2
COVID-19
Variants of Concern (VOCs)
title_short Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
title_full Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
title_fullStr Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
title_full_unstemmed Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
title_sort Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
author Azevedo, Patrick Orestes
author_facet Azevedo, Patrick Orestes
Souza, Natália Satchiko Hojo de
Faustino, Lídia Paula
Fumagalli, Marcílio Jorge
Hirako, Isabella Cristina
Oliveira, Emiliano R.
Figueiredo, Maria M.
Carvalho, Alex F.
Doro, Daniel
Benevides, Luciana
Durigon, Edison
Fonseca, Flávio Guimaraes
Machado, Alexandre Magalhaes
Fernandes, Ana P.
Teixeira, Santuza Maria Ribeiro
Silva, João S.
Gazzinelli, Ricardo Tostes
author_role author
author2 Souza, Natália Satchiko Hojo de
Faustino, Lídia Paula
Fumagalli, Marcílio Jorge
Hirako, Isabella Cristina
Oliveira, Emiliano R.
Figueiredo, Maria M.
Carvalho, Alex F.
Doro, Daniel
Benevides, Luciana
Durigon, Edison
Fonseca, Flávio Guimaraes
Machado, Alexandre Magalhaes
Fernandes, Ana P.
Teixeira, Santuza Maria Ribeiro
Silva, João S.
Gazzinelli, Ricardo Tostes
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Azevedo, Patrick Orestes
Souza, Natália Satchiko Hojo de
Faustino, Lídia Paula
Fumagalli, Marcílio Jorge
Hirako, Isabella Cristina
Oliveira, Emiliano R.
Figueiredo, Maria M.
Carvalho, Alex F.
Doro, Daniel
Benevides, Luciana
Durigon, Edison
Fonseca, Flávio Guimaraes
Machado, Alexandre Magalhaes
Fernandes, Ana P.
Teixeira, Santuza Maria Ribeiro
Silva, João S.
Gazzinelli, Ricardo Tostes
dc.subject.en.none.fl_str_mv SARS-CoV-2
COVID-19
Variants of Concern (VOCs)
topic SARS-CoV-2
COVID-19
Variants of Concern (VOCs)
description Universidade Federal de Minas Gerais. Centro de Tecnologia de Vacinas. Belo Horizonte, MG, Brazil / Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
publishDate 2023
dc.date.accessioned.fl_str_mv 2023-03-14T18:45:40Z
dc.date.available.fl_str_mv 2023-03-14T18:45:40Z
dc.date.issued.fl_str_mv 2023
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv AZEVEDO, Patrick Orestes et al. Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. NPJ Vaccines, v. 8, p. 1-17, 2023.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/57372
dc.identifier.issn.en_US.fl_str_mv 2059-0105
dc.identifier.doi.none.fl_str_mv 10.1038/s41541-023-00616-y
identifier_str_mv AZEVEDO, Patrick Orestes et al. Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. NPJ Vaccines, v. 8, p. 1-17, 2023.
2059-0105
10.1038/s41541-023-00616-y
url https://www.arca.fiocruz.br/handle/icict/57372
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Nature
publisher.none.fl_str_mv Nature
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/57372/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/57372/2/Differential%20requirement%20of%20neutralizing%20antibodies%20and%20T%20cells%20on%20protective%20immunity%20to%20SARS-CoV-2%20variants%20of%20concern.pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
081754fe85f7ba91d31f7803c1fa0fa0
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008880106471424

Registros relacionados